104 related articles for article (PubMed ID: 8101201)
1. Development of resistance to aminoglycosides among coagulase-negative staphylococci and enterobacteriaceae in a neonatal intensive care unit.
Krediet TG; Fleer A; Gerards LJ
J Hosp Infect; 1993 May; 24(1):39-46. PubMed ID: 8101201
[TBL] [Abstract][Full Text] [Related]
2. Staphylococcal resistance to aminoglycosides before and after introduction of amikacin in two teaching hospitals.
Hammerberg O; Elder D; Richardson H; Landis S
J Clin Microbiol; 1986 Oct; 24(4):629-32. PubMed ID: 3771751
[TBL] [Abstract][Full Text] [Related]
3. Resistance of gram-negative bacilli and staphylococci from blood cultures to aminoglycoside antibiotics. Comparison of 3 in vitro investigations from Austria 1982-1988.
Mittermayer H; Rotter M; Breitfellner G; Riezinger F; Thiel W; Binder L; Watschinger R
Zentralbl Bakteriol; 1990 Apr; 272(4):448-57. PubMed ID: 2113808
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and genotypic aminoglycoside resistance in blood culture isolates of coagulase-negative staphylococci from a single neonatal intensive care unit, 1989-2000.
Klingenberg C; Sundsfjord A; Rønnestad A; Mikalsen J; Gaustad P; Flaegstad T
J Antimicrob Chemother; 2004 Nov; 54(5):889-96. PubMed ID: 15471996
[TBL] [Abstract][Full Text] [Related]
5. [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].
Schassan HH
Infection; 1976; 4(2):35-41. PubMed ID: 789246
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and mechanisms of aminoglycoside resistance. A ten-year study.
Phillips I; King A; Shannon K
Am J Med; 1986 Jun; 80(6B):48-55. PubMed ID: 3728534
[TBL] [Abstract][Full Text] [Related]
7. Analysis of neomycin, kanamycin, tobramycin and amikacin resistance mechanisms in gentamicin-resistant isolates of Enterobacteriaceae.
Adwan K; Abu-Hasan N; Al-Asmar H
J Med Microbiol; 1998 Nov; 47(11):1019-21. PubMed ID: 9822302
[TBL] [Abstract][Full Text] [Related]
8. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
Moellering RC; Wennersten C; Kunz LJ; Poitras JW
Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of netilmicin, gentamicin, tobramycin and amikacin against glucose fermenting and nonfermenting bacteria.
DiPersio JR; Krafczyk TL
Chemotherapy; 1980; 26(5):323-33. PubMed ID: 7389428
[TBL] [Abstract][Full Text] [Related]
11. In vitro aminoglycoside resistance of gram-negative bacilli and staphylococci isolated from blood in Sweden 1980-1984.
Bengtsson S; Bernander S; Brorson JE; Dornbusch K; Forsgren A; Hallander H; Henning C; Holm S; Malmborg AS; Nilsson L
Scand J Infect Dis; 1986; 18(3):257-63. PubMed ID: 3738436
[TBL] [Abstract][Full Text] [Related]
12. Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates.
Price KE; DeFuria MD; Pursiano TA
J Infect Dis; 1976 Nov; 134 SUPPL():S249-61. PubMed ID: 62814
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin.
Knothe H
J Infect Dis; 1976 Nov; 134 SUPPL():S271-4. PubMed ID: 825585
[TBL] [Abstract][Full Text] [Related]
14. Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses.
Orsini JA; Benson CE; Spencer PA; Van Miller E
Am J Vet Res; 1989 Jun; 50(6):923-5. PubMed ID: 2669575
[TBL] [Abstract][Full Text] [Related]
15. [The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)].
Jotzoff M
Med Klin; 1978 Jun; 73(24):914-7. PubMed ID: 661734
[TBL] [Abstract][Full Text] [Related]
16. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer centres with aminoglycoside usage.
Muscato JJ; Wilbur DW; Stout JJ; Fahrlender RA
J Antimicrob Chemother; 1991 May; 27 Suppl C():1-7. PubMed ID: 1906860
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of aminoglycoside resistance. European data.
Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
[TBL] [Abstract][Full Text] [Related]
19. Gentamicin and amikacin---an in vitro comparison using 1000 clinical isolates.
Forgan-Smith WR; McSweeney RJ
Aust N Z J Med; 1978 Aug; 8(4):383-6. PubMed ID: 282852
[TBL] [Abstract][Full Text] [Related]
20. In vitro interaction between cefotetan and aminoglycosides on Staphylococcus aureus and coagulase negative staphylococci, both methicillin-susceptible and -resistant.
Stefani S; Debbia E; Schito GC; Nicoletti G
Chemioterapia; 1988 Jun; 7(3):151-5. PubMed ID: 3168069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
